Prognostic significance of non-papillary tumor morphology as a predictor of cancer progression and survival in patients with primary T1G3 bladder cancer

Park, Jinsung; Song, Cheryn; Hong, Jun Hyuk; Park, Bong-Hee; Cho, Yong Mee; Kim, Choung‐Soo; Ahn, Hanjong

doi:10.1007/s00345-008-0350-4

Cited by 24 publications

(19 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As reported previously, once progression to invasive cancer (pT2‐4) occurs, the median survival rate is just 12–15 months, and this has not been improved over the past two decades, despite the development and use of different chemotherapeutic treatment approaches 18 . Therefore, identification of prognostic clinicopathological factors, especially in relation to tumor recurrence and progression, is crucial to manage UC optimally 19 …”

Section: Discussionmentioning

confidence: 99%

“…18 Therefore, identification of prognostic clinicopathological factors, especially in relation to tumor recurrence and progression, is crucial to manage UC optimally. 19 Although tumor grade and stage are the most accurate prognostic factors in the evaluation of bladder UC, they cannot always predict the true tumor biological potential, as non-muscle invasive tumors of the same stage and grade can have completely different clinical courses. 4 Furthermore, non-muscle invasive UC is a heterogeneous spectrum of diseases with different biological and clinical behaviors, determined by distinct molecular alterations.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Overexpression of Eg5 predicts unfavorable prognosis in non‐muscle invasive bladder urothelial carcinoma

Ding

Xing²,

Lü³

et al. 2011

Int J of Urology

View full text Add to dashboard Cite

Objective: To investigate the relationship between Eg5 expression and prognosis of patients with non-muscle invasive bladder urothelial carcinoma. Methods: Eg5 expression was examined by immunohistochemistry in non-muscle invasive urothelial carcinoma specimens (grade: G1, 32 cases; G2, 92 cases; and G3, 39 cases. Stage: pTa, 49 cases and pT1, 114 cases). The correlation between clinicopathological characteristics and Eg5 expression was evaluated. The prognostic significance of Eg5 immunoreactivity was analyzed through survival analysis in 163 non-muscle invasive cases that were treated with transurethral resection and adjuvant intravesical instillations. Results: The expression of Eg5 was significantly associated with tumor grade (P = 0.006), with a trend towards significant association with stage (P = 0.057). The 163 patients with non-muscle invasive tumors were regularly followed with the mean of 32.52 (from 6 to 72) months. Univariate analysis showed Eg5 overexpression exhibited a significant unfavorable influence on intravesical recurrence (P = 0.012) while having only a marginal correlation with disease progression (P = 0.070). Subsequent Cox hazard multivariate analysis showed that both grade (P = 0.045) and Eg5 expression (P = 0.029) were independent predictors for early intravesical recurrence. Conclusions: Overexpression of Eg5 correlates with poor differentiation of bladder cancer, and it represents an independent prognostic factor in predicting early intravesical recurrence in non-muscle invasive bladder carcinoma patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Overexpression of Eg5 predicts unfavorable prognosis in non‐muscle invasive bladder urothelial carcinoma

Ding

Xing²,

Lü³

et al. 2011

Int J of Urology

View full text Add to dashboard Cite

show abstract

“…Okajima et al (11) reported that patients with non-papillary tumors had significantly worse CSS than did patients with papillary tumors. Park et al (12) reported that non-papillary tumors were associated with the presence of lymphovascular invasion and CIS. Additionally, other reports showed that lymphovascular invasion was an independent prognostic factor for T1 bladder cancer (22,23).…”

Section: Discussionmentioning

confidence: 99%

Impact of divergent differentiation in urothelial carcinoma on oncological outcome in patients with T1 high-grade bladder cancer

Fujii

Hoshii

Hirata

et al. 2017

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

Objective: T1 high-grade bladder cancer has a poor prognosis compared with other non-muscleinvasive bladder cancers. We investigated the clinical outcomes among patients with T1 highgrade bladder cancer to identify factors related to cancer recurrence and disease progression. Methods: We retrospectively reviewed the data of 148 patients who were diagnosed with T1 highgrade bladder cancer by transurethral resection from January 2001 to February 2015 at our institution. Clinicopathological factors were analyzed using univariate and multivariate analyses. Results: The median age and follow-up duration were 72 years and 45.4 months, respectively. Sixty-two patients (41.9%) had recurrence, 28 (18.9%) experienced progression and 13 (8.8%) died of bladder cancer. In the multivariate analysis, divergent differentiation was an independent factor related to recurrence (P = 0.0096, hazard ratio = 2.5), whereas a non-papillary tumor shape, divergent differentiation and presence of a residual tumor at the time of the second transurethral resection were independent factors related to progression (P = 0.0349, hazard ratio = 3.8; P = 0.0074, hazard ratio = 6.8 and P = 0.0449, hazard ratio = 4.1, respectively). There were no independent factors related to cancer-specific mortality. Divergent differentiation was the only independent factor associated with both recurrence and progression. In addition, patients with divergent differentiation had significantly worse recurrence-free survival and progression-free survival rates than did patients without divergent differentiation (log-rank P = 0.0009 and P = 0.0019, respectively). Conclusions: In this study, the presence of divergent differentiation was related to worse oncological outcomes in patients with T1 high-grade bladder cancer. Patients with divergent differentiation may require stringent follow-up and early cystectomy after recurrence to improve oncological outcomes.

show abstract

“…Transurethral resection of the bladder (TURB) was performed with curative intent by 2 surgeons (H.A and C.S.K), and our detailed TURB technique was addressed in a prior study [12]. All patients received intravesical BCG therapy consisting of 6 weekly instillations of oncotice strain BCG (12.5 mg in 50 ml saline) within 2ϳ4 weeks after surgery.…”

Section: Patient Populationmentioning

confidence: 99%

“…Prior studies have suggested that several clinicopathologic parameters, such as tumor size [10,11], multiplicity [10], morphology [12], concomitant carcinoma-in-situ (CIS) [10,11], and response to intravesical therapy [13] are risk factors for tumor progression and patient mortality in T1G3 BC. However, the results of these studies are inconsistent; meanwhile, some studies found no prognostic value of such clinicopathologic parameters in T1G3 BC [14].…”

Section: Introductionmentioning

confidence: 99%

Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy?

Park

Song

Shin

et al. 2013

Urologic Oncology: Seminars and Original Investigations

Self Cite

View full text Add to dashboard Cite

Prognostic significance of non-papillary tumor morphology as a predictor of cancer progression and survival in patients with primary T1G3 bladder cancer

Abstract: Non-papillary tumor morphology was a predictor of cancer progression and survival in patients with primary T1G3 BC.

Cited by 24 publications

References 23 publications

Overexpression of Eg5 predicts unfavorable prognosis in non‐muscle invasive bladder urothelial carcinoma

Overexpression of Eg5 predicts unfavorable prognosis in non‐muscle invasive bladder urothelial carcinoma

Impact of divergent differentiation in urothelial carcinoma on oncological outcome in patients with T1 high-grade bladder cancer

Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy?

Contact Info

Product

Resources

About